[Geroprotective effect of thymalin and epithalamin]. — VialBase Research

Summary

This paper, published in Russian in Advances in Gerontology (Uspekhi gerontologii) with only an English abstract available, reports the clinical geroprotection work conducted by researchers of the St. Petersburg Institute of Bioregulation and Gerontology (North-Western Branch of the Russian Academy of Medical Sciences) together with the Research Institute of Gerontology of the Ukrainian Academy of Medical Sciences in Kiev. The authors state that the thymic peptide bioregulator Thymalin and the epiphyseal bioregulator Epithalamin were clinically assessed in 266 elderly and older persons across 6-8 years of observation, with the bioregulators actually administered only during the first 2-3 years of that window. The reported results describe normalization of basic organism functions — improvement in cardiovascular, endocrine, immune, and nervous system indices, homeostasis, and metabolism — accompanied by a 2.0-2.4-fold decrease in acute respiratory disease incidence and reduced clinical manifestations of ischemic heart disease, hypertension, deforming osteoarthrosis, and osteoporosis relative to control. The headline claim is a mortality reduction over the observation period: 2.0-2.1-fold among Thymalin-treated patients, 1.6-1.8-fold in the Epithalamin group, 2.5-fold with Thymalin combined with Epithalamin, and 4.1-fold in a separate group treated with the combination annually for six years. The authors conclude that both peptides have high geroprotective efficacy and should be applied in medicine and social care for persons over 60. Two structural caveats are inseparable from these numbers: the report is Russian-language with an English abstract only, and it originates from the same institute that developed and promotes these preparations.

Key Findings

• 266 elderly and older persons were observed for 6-8 years; Thymalin and/or Epithalamin were administered only during the first 2-3 years of that period
• Reported normalization of cardiovascular, endocrine, immune, and nervous system indices, plus homeostasis and metabolism, in treated patients
• Reported 2.0-2.4-fold decrease in acute respiratory disease incidence versus control, alongside reduced incidence of ischemic heart disease manifestations, hypertension, deforming osteoarthrosis, and osteoporosis
• Reported mortality reduction versus control: 2.0-2.1-fold (Thymalin), 1.6-1.8-fold (Epithalamin), 2.5-fold (combination); a subgroup receiving the combination annually for 6 years is reported at 4.1-fold lower mortality
• The record is indexed as Russian-language with an English abstract and is classified as a Review; the work is attributed to the St. Petersburg Institute of Bioregulation and Gerontology and the Kiev Research Institute of Gerontology

Relevance to Thymalin

Nearly every longevity claim made for Thymalin in the consumer market traces back to this paper, so it deserves to be read carefully rather than quoted as a headline. The effect sizes reported here are extraordinary — a 4.1-fold mortality reduction is far larger than anything achieved by any approved pharmaceutical intervention in geriatric medicine — and extraordinary effect sizes from a single research group carry a correspondingly heavy replication burden. This literature sits well below FDA evidentiary grade: it is a Russian-language review whose full methods are not accessible in English, published in a journal of the same national research tradition that produced the compound, by the group at the St. Petersburg Institute of Bioregulation and Gerontology that developed and continues to promote the Khavinson peptide bioregulators. None of that makes the findings false, but it does mean they remain unreplicated by independent Western investigators and should never be presented to a reader as established clinical fact. The honest framing is that Thymalin has a large body of favourable in-house Russian clinical literature and effectively no independent confirmatory trials.

Citation

Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Advances in gerontology = Uspekhi gerontologii. 2002;10:74-84. [Article in Russian; English abstract available.]

See Also

• Parent compound: Thymalin